Stay updated on Phase II Nivolumab Plus Ipilimumab in Sarcoma & Endometrial Clinical Trial
Sign up to get notified when there's something new on the Phase II Nivolumab Plus Ipilimumab in Sarcoma & Endometrial Clinical Trial page.

Latest updates to the Phase II Nivolumab Plus Ipilimumab in Sarcoma & Endometrial Clinical Trial page
- Check2 days agoChange DetectedAdded a site-wide notice about government funding delays and updated the page revision to v3.4.1. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.4%

- Check9 days agoChange DetectedAdded a 'Show glossary' toggle and updated labels and revision information (capitalization changes for QC-related fields; Revision: v3.4.0, replacing v3.3.4).SummaryDifference0.2%

- Check16 days agoChange DetectedCore study details such as eligibility criteria, outcomes, and treatment arms remain unchanged. The observed differences are minor formatting and wording edits.SummaryDifference0.1%

- Check24 days agoChange DetectedRevision: v3.3.4 replaces v3.3.3; this appears to be a small metadata/UI update and does not affect study content.SummaryDifference0.2%

- Check45 days agoChange DetectedAdded Revision: v3.3.3 to the page; removed HHS Vulnerability Disclosure and Revision: v3.3.2.SummaryDifference0.2%

- Check67 days agoChange DetectedMinor system revision updating from v3.3.1 to v3.3.2, with no visible changes to study content, eligibility, or contact details.SummaryDifference0.2%

Stay in the know with updates to Phase II Nivolumab Plus Ipilimumab in Sarcoma & Endometrial Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Phase II Nivolumab Plus Ipilimumab in Sarcoma & Endometrial Clinical Trial page.